Evidence map›Paper›PMID 27131863›Full record

ReviewBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2016

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.

Timothy S Fenske, Mehdi Hamadani, Jonathon B Cohen, Luciano J Costa, Brad S Kahl, Andrew M Evens, Paul A Hamlin, Hillard M Lazarus, Effie Petersdorf, Christopher Bredeson

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 46 citations in OpenAlex.

  1. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Trial
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Advances in Immunotherapy for Diffuse Large B Cell Lymphoma.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021
    Review
  13. Article
  14. Immunotherapy with cells.Hematology. American Society of Hematology. Education Program · 2020
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 2 countries.

Timothy S FenskeDivision of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: tfenske@mcw.edu.
Mehdi HamadaniDivision of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin; Center for International Blood and Marrow Transplant Research, Milwaukee, Wisconsin.
Jonathon B CohenDepartment of Hematology and Medical Oncology, Emory University, Winship Cancer Institute, Atlanta, Georgia.
Luciano J CostaDivision of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
Brad S KahlDivision of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Andrew M EvensDivision of Hematology/Oncology, Tufts Medical Center, Boston, Massachusetts.
Paul A HamlinDepartment of Medicine, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York.
Hillard M LazarusDivision of Hematology-Oncology, Department of Medicine, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio.
Effie PetersdorfDivision of Medical Oncology, University of Washington School of Medicine, and Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Christopher BredesonBlood and Marrow Transplant Program, Ottawa Hospital Research Institute at University of Ottawa, Ottawa, Ontario, Canada.
Medical College of Wisconsin · USFred Hutch Cancer Center · USNew York Hospital Queens · USTufts Medical Center · USUniversity Hospitals Case Medical Center · USUniversity of Alabama at Birmingham · USUniversity of Ottawa · CAWashington University in St. Louis · USWinship Cancer Institute

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
NCI NIH HHS P30 CA008748NCI NIH HHS U24 CA076518
6 · The paper itself

Abstract

Non-Hodgkin lymphoma (NHL) constitutes a collection of lymphoproliferative disorders with widely varying biological, histological, and clinical features. For the B cell NHLs, great progress has been made due to the addition of monoclonal antibodies and, more recently, other novel agents including B cell receptor signaling inhibitors, immunomodulatory agents, and proteasome inhibitors. Autologous hematopoietic cell transplantation (auto-HCT) offers the promise of cure or prolonged remission in some NHL patients. For some patients, however, auto-HCT may never be a viable option, whereas in others, the disease may progress despite auto-HCT. In those settings, allogeneic HCT (allo-HCT) offers the potential for cure. Over the past 10 to 15 years, considerable progress has been made in the implementation of allo-HCT, such that this approach now is a highly effective therapy for patients up to (and even beyond) age 75 years. Recent advances in conventional lymphoma therapy, peritransplantation supportive care, patient selection, and donor selection (including the use of alternative hematopoietic cell donors), has allowed broader application of allo-HCT to patients with NHL. As a result, an ever-increasing number of NHL patients over age 60 to 65 years stand to benefit from allo-HCT. In this review, we present data in support of the use of allo-HCT for patients with diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma. These histologies account for a large majority of allo-HCTs performed for patients over age 60 in the United States. Where possible, we highlight available data in older patients. This body of literature strongly supports the concept that allo-HCT should be offered to fit patients well beyond age 65 and, accordingly, that this treatment should be covered by their insurance carriers.

Indexed as

AgedDonor SelectionHematopoietic Stem Cell TransplantationHumansLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, Non-HodgkinMiddle AgedTransplantation, HomologousAllogeneic hematopoietic cell transplantationElderlyNon-Hodgkin lymphomaReduced-intensity conditioning

Identifiers

PMID27131863
PMCPMC4981559
OpenAlexW2344483783

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.